Assessment of Direct Oral Anticoagulant Prescribing and Monitoring Pre- and Post-Implementation of a Pharmacy Protocol at a Community Teaching Hospital

Abstract

Background

Direct oral anticoagulants (DOACs) have become popular alternatives to vitamin K antagonists for the treatment and prevention of thromboembolic diseases; however, there are limited data regarding the appropriate use of DOACs in clinical practice. To ensure safety and efficacy of these medications, it is important that decisions regarding their use in patients rely on the available evidence.

Objective

The purpose of this study was to evaluate the appropriateness of DOAC prescribing in adult patients before and after the implementation of a pharmacist-driven DOAC protocol.

Methods

Data were collected on adult patients admitted to a community teaching hospital who received DOAC therapy for at least 2 days between January and March 2015 (pre-intervention group) and between January and March 2016 (post-intervention group). These data were analyzed to measure inappropriately prescribed DOACs, defined based on DOAC indication, renal function, drug interactions, and other pertinent patient-specific factors. Prior to the start of data collection for the post-intervention group, a pharmacist-driven protocol was developed and implemented. DOAC education was provided to pharmacists, including an evidence-based prescribing table to guide appropriate DOAC therapy. Comparisons were made between the pre-intervention and post-intervention groups to determine the impact of the pharmacist-driven service on appropriate DOAC prescribing.

Results

Fifty patients were analyzed in the pre-intervention group compared with 85 patients in the post-intervention group, with a total of 333 and 816 doses administered, respectively. Of the total doses administered, 32.4% were considered inappropriate in the pre-intervention group compared with 13.8% in the post-intervention group (adjusted odds ratio [OR], 0.42, 95% CI, 0.19-0.96; p = 0.039).

Conclusions

Implementing a pharmacist-driven DOAC service significantly improved appropriate prescribing of these agents. Provider education regarding DOAC use is essential to further increase appropriate prescribing of DOACs, optimize patients' therapy, and prevent adverse drug events.

Keywords

anticoagulation apixaban dabigatran etexilate DOAC drug interactions edoxaban

Get full access to this article

View all access options for this article.

References

January

C.T.

, Wann

L.S.

, Alpert

J.S.

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Amer Coll Cardiol. 2014; 64(21): 2246–2280.

Beckman

M.G.

, Hooper

W.C.

, Critchley

S.E.

Venous thromboembolism: A public health concern. Am J Prev Med. 2010; 38(4 suppl): S495–501.

US Department of Health and Human Services, Office of Disease Prevention and Health Promotion. National action plan for adverse drug event prevention. http://health.gov/hcq/pdfs/ADE-Action-Plan-Anticoagulants.pdf. Accessed August 18, 2015.

The Joint Commission. Hospital: 2015 National Patient Safety Goals. http://www.jointcommission.org/assets/1/6/2015_NPSG_HAP.pdf. Accessed August 1, 2015.

Eliquis® (apixaban) tablets [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; 2015.

Pradaxa® (etexilate mesylate) capsules [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2015.

Savaysa® (edoxaban) tablets [prescribing information]. Parsippany, NJ: Daiichi Sankyo; 2015.

Xarelto® (rivaroxaban) tablets [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals; 2015.

Barnes

G.D.

, Lucas

, Alexander

G.C.

National trends in ambulatory oral anticoagulant use. Am J Med. 2015; 128(12): 1300–1305.e2.

10.

Connolly

S.J.

, Ezekowitz

M.D.

, Yusuf

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139–1151.

11.

Patel

M.R.

, Mahaffey

K.W.

, Garg

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883–891.

12.

Granger

C.B.

, Alexander

J.H.

, McMurray

J.J.V.

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981–992.

13.

Giugliano

R.P.

, Ruff

C.T.

, Braunwald

Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22): 2093–2104.

14.

Van der Hulle

, Koolman

, den Exter

P.L.

Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: A systematic review and meta-analysis. J Thromb Haemost. 2014; 12(3): 320–328.

15.

Holster

I.L.

, Valkhoff

V.E.

, Kuipers

E.J.

New oral anticoagulants increase risk for gastrointestinal bleeding: A systematic review and meta-analysis. Gastroenterology. 2013; 145: 105–112.

16.

Harel

, Scholzberg

, Shah

P.S.

Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. J Am Soc Nephrol. 2014; 25(3): 431–442.

17.

Lega

J.C.

, Bertoletti

, Gremillet

Consistency of safety profiles of new oral anticoagulants in patients with renal failure. J Thromb Haemost. 2014; 12: 337–343.

18.

Basaran

, Filiz Basaran

, Cekic

E.G.

Prescription patterns of oral anticoagulants in nonvalvular atrial fibrillation (Proper Study) [pubished online ahead of print October 30, 2015]. Clin Appl Thromb Hemost.

19.

Schillig

, Kaatz

, Hudson

Clinical and safety impact of an inpatient pharmacist-directed anticoagulation service. J Hosp Med. 2011; 6(6): 322–328.

20.

Bond

C.A.

, Raehl

C.L.

Pharmacist-provided anticoagulation management in United States hospitals: Death rates, length of stay, Medicare charges, bleeding complications, and transfusions. Pharmacotherapy. 2004; 24(8): 953–963.

21.

Tellor

K.B.

, Patel

, Armbruster

A.L.

Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital. J Clin Pharm Ther. 2015; 40(4): 447–451.

22.

Larock

A.S.

, Mullier

, Sennesael

A.L.

Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: A prospective study. Ann Pharmacother. 2014; 48(10): 1258–1268.